Intertek is preparing to reject EQT’s latest £10bn takeover offer, marking a pivotal moment in the saga over the UK testing firm. The Swedish private equity group raised its bid to £58 per share, a 54% premium to Intertek’s April 9 closing price of £37.70, but the company’s board deems it insufficient. Sources indicate Intertek views the proposal as undervaluing its worth, echoing its rejection of prior £51.50 and £54 offers. EQT, however, remains optimistic, framing the £8.9bn equity-value bid as a step toward “prompt engagement.” The company’s stance could shape market dynamics, especially as Intertek’s strategic review—spurred by activist investor Matt Peltz’s stake—explores spinning off energy and infrastructure assets. Intertek and EQT have not commented, but the tension underscores broader investor scrutiny of the testing industry’s valuation.

The bid’s trajectory reflects EQT’s aggressive pursuit of Intertek, which has previously resisted lower offers. The £10.3bn total value, including debt, positions this as one of the largest deals in Intertek’s history. Yet, the company’s focus on strategic restructuring complicates a straightforward acquisition. Peltz’s involvement adds another layer, as his pressure for a breakup aligns with Intertek’s exploration of demergers. This standoff highlights the volatility in FTSE 100 valuations, where activist pressures and private equity bids intersect. Intertek’s decision this week could set a precedent for how firms navigate overlapping shareholder agendas.

The outcome hinges on EQT’s ability to renegotiate terms or Intertek’s resolve to prioritize its strategic review. With UK takeover regulations requiring EQT to finalize its offer by May 14, the clock is ticking. A rejection would likely trigger further market volatility, particularly for Intertek’s shareholders betting on a higher valuation. Conversely, a successful deal could signal private equity’s renewed appetite for mid-cap UK firms. However, Intertek’s path forward remains uncertain, balancing financial offers against operational priorities. The stakes are clear: a £10bn transaction could redefine Intertek’s role in global testing markets—or fracture it into separate entities.